Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus
Bausch + Lomb Corporation (NYSE: BLCO ) on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma after the candidate failed to meet the primary endpoint in a Phase 2 clinical trial. Trial Misses Primary And Key Secondary Endpoints The randomized, double-masked, three-arm, parallel